• Acta clinica Croatica · Sep 2018

    Review

    BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.

    • Bogeljić PatekarMartinaM1Division of Hematology, Merkur University Hospital, Zagreb, Croatia; 2Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of America; 3School of Medicine, University of Zagreb, Zagreb, Croa, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, and Ostojić KolonićSlobodankaS1Division of Hematology, Merkur University Hospital, Zagreb, Croatia; 2Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of America; 3School of Medicine, University of Zagreb, Zagreb, Cr.
    • 1Division of Hematology, Merkur University Hospital, Zagreb, Croatia; 2Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of America; 3School of Medicine, University of Zagreb, Zagreb, Croatia.
    • Acta Clin Croat. 2018 Sep 1; 57 (3): 542553542-553.

    Abstract- The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown efficacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fit patients, as defined in CLL10 study, B-R has yielded a more beneficial toxicity profile and its use in first line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…